An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

Inclusion Criteria: * Written informed consent and HIPAA authorization. * Age between 18 and 65 years * Male and female subjects with clinically definite or laboratory-supported definite relapsing-remitting multiple sclerosis * A minimum disease level according to the McDonald criteria for the definition of MS based on results of an MRI scan; acquired within 1 year (Subjects with other significant abnormal findings will be excluded) * Receiving consistent therapy with Copaxone® or Avonex® for at least 1 year. * Expanded Disability Status Score (EDSS) of 0 to ≤ 5.5, inclusive * Exhibiting low or medium level of concern within 12 months prior to screening based on: relapses, or clinical progression, or MRI progression * Clinical stability or improving neurological state during the eight weeks before Study Day 0 * Willingness \& ability to comply with the protocol for the duration of the study * Confirmation that a subject capable of having children is not pregnant must be established by a negative urine pregnancy test within 30 days of Screening and a negative urine pregnancy test on Scan Days. Exclusion Criteria: * Pregnant or lactating women, or women of childbearing potential not using an acceptable method of contraception * Progressive forms of MS (Primary progressive, Secondary progressive) * Exhibiting a high level of concern within 12 months prior to screening based on: relapses, or clinical progression, or MRI progression * Subjects who have been on DMTs other than Copaxone® or Avonex® for longer than 3 months * Subjects who have been on Avonex® or Copaxone® for less than 3 months and have exhibited intolerability * History of hypersensitivity to natural or recombinant interferon beta, human serum albumin, or any other component of the Avonex® formulation (for Avonex® Group A) * History of hypersensitivity to glatiramer acetate or mannitol, or any other component of the Copaxone® formulation (for Copaxone® Group B) * Participation in any other studies involving investigational or marketed products, concomitantly or within 30 days prior to screening * Treatment with oral or systemic corticosteroids or ACTH within 4 weeks of screening or ongoing chronic treatment with systemic corticosteroids. * Treatment with immunomodulatory or immunosuppressive therapy (including but not limited to cyclophosphamide, cyclosporine, methotrexate, azathiprine,linomide, mitoxantrone, Campath) within the 12 months prior to study day 0 * Prior cytokine or anti-cytokine therapy within 3 months prior to Study Day 0 * Prior use of cladribine or have received total lymphoid irradiation * Have taken intravenous immunoglobulin or any other investigational drug or taken part in any experimental procedure in the 6 months prior to screening * Psychiatric disorder that is unstable or would preclude safe participation in the study * Cognitive impairment which impairs ability to understand or comply with the protocol procedures * Significant leucopenia (white blood cell count \<0.5 times the lower limit of normal)as assessed during the course of routine standard of care * Elevated liver function tests (ALT, AST, alkaline phosphatase or total bilirubin \>2 times the upper limit of normal) as assessed during the course of routine standard of care * Specific systemic diseases, (including insulin-dependent diabetes, Lyme disease,clinically significant cardiac disease, HIV, HTLV-1, and Hepatitis B or C), or other uncontrolled major medical conditions (depression, seizure disorder) that would interfere with the participant's safety, compliance or evaluation * Unable and/or unlikely to follow the protocol for any reason * Alcohol and/or any other drug abuse * Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol * Abnormal baseline clinical findings considered by the investigator to be indicative of conditions that might affect study results * Impaired renal function, as shown by but not limited to serum creatinine \>2.5 mg/dL * Subjects who cannot take the FDA approved medication for any reason will be excluded * Corticosteroids allowed at doses between 500 mg and 1000 mg IV (over 3-5 days for relapses) IV for a maximum of three days In addition, specific exclusion criteria are required for MRI scanning: * Ferrous objects within the body * Pregnancy * Weight inappropriate for height * Low visual acuity that cannot be corrected with glasses * History of claustrophobia * Participants whose high-resolution anatomic MR scans reveal the presence of a structural abnormality (other than MS). * Standard protocol for monitoring based on FDA approved medication will be followed